Revvity receives FDA approval for automated latent tuberculosis test
GRevvity, Inc. has secured US Food and Drug Administration approval for its Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test, enhancing laboratory capabilities for latent tuberculosis detection. The technology, already available outside the US since 2024, enables higher testing volumes whilst maintaining clinical accuracy in this critical infectious disease diagnostic area.













